The standards for drugs entering first-in-human (FIH) clinical trials are too low, argues Associate Professor Dr. Jonathan Kimmelman and PhD candidate Carole Federico in McGill’s Biomedical Ethics Unit. In a commentary published online in Nature on Jan. 30, Kimmelman and Federico maintain that evidence for drug efficacy is not emphasized enough before[Read More…]
Search Results for author "Palma Gubert"
The case for eradicating malaria with gene-editing technologies
What if we could rid the world of any species that we didn’t like: The annoying ones, the dangerous ones, and the disease-spreading ones? This seems like a tall order and one that carries a number of ethical quandaries. With the advent of CRISPR/Cas9 gene technologies, the once theoretical bioethics[Read More…]
